Close
FINDING CURES TOGETHER<sup>SM</sup>

AACR Annual Meeting 2019

Spotlight on Clinical Trials 

Clinical Trials Abstract Submission Deadline: Thursday, Jan. 10, 2019

Submit Your Clinical Trials Abstracts to the AACR Annual Meeting 2019
Become a part of our growing science-based clinical research program at the Annual Meeting and help us showcase how research continues to transform the lives of cancer patients.

Why You Should Submit

  • Numerous and unique oral presentation opportunities
    • Four Clinical Trials Plenary Sessions offering companion presentations explaining the science behind the presented trials
    • Three Clinical Trials Minisymposia
  • Poster presentations
  • Potential national media coverage through the extensive AACR press program
  • Opportunities to simultaneously present your work and publish a manuscript in a high-impact AACR journal
    • If you will have a complete manuscript ready to submit by late January, select the appropriate options during the abstract submission process.
    • If accepted, your abstract and manuscript may be presented and published simultaneously, in addition to being included in the press program.
    • Contact pubs@aacr.org with any questions or to indicate your interest in submitting a manuscript.
  • No restrictions on presenters as long as the presentation is CME-compliant

What to Submit
View clinical trial (CT) abstract submission categories

  • Any phase (I, II, III, or any combination) abstract from national or international clinical trials
    • Biomarker studies: If the abstract describes a predefined biomarker analysis that was part of the original trial design and trial data will be reported, then it may be submitted to a clinical trials category. If the biomarker analysis was not part of the original trial design or was performed post hoc, then the abstract should be submitted to a Clinical Research category (CL11 Biomarkers) for the Nov. 15 deadline (or as a late-breaking Clinical Research abstract on Jan. 10 if the study is not complete by Nov. 15).
  • Promising ongoing trials or unique trial designs that have not yet yielded results to the Clinical Trials in Progress category (CT07). (Note that placeholder abstracts are not permitted for Trials in Progress.) 
  • Encore presentations

When to Submit

  • Submit your completed or placeholder abstract(s) by the Jan. 10, 2019 deadline for clinical trials and late-breaking abstracts. The clinical trials (CT) abstract categories will not be available for submissions for the Nov. 15, 2018 deadline.
  • Final results and conclusions for placeholder abstracts are due by Feb. 1, 2019.

Clinical Trials (Including Combination Trials) Abstract Categories

  • CT01 Phase I Adult Clinical Trials
    • See also ET05: Pharmacology, Pharmacogenetics, and Pharmacogenomics
  • CT02 Phase II Adult Clinical Trials
  • CT03 Phase III Adult Clinical Trials
  • CT04 Phase I, II, or III Clinical Trials in Pediatric Cancer
  • CT05 Phase I, II, or III Clinical Trials in the Elderly
  • CT06 Phase I, II, or III Clinical Trials in Minorities and Medically Underserved Populations
  • CT07 Clinical Trials in Progress
    • Phase I Clinical Trials
    • Phase II Clinical Trials
    • Phase III Clinical Trials

Placeholder Abstract Categories

  • PL01 Phase I Adult Clinical Trials
  • PL02 Phase II Adult Clinical Trials
  • PL03 Phase III Adult Clinical Trials
  • PL04 Phase I, II, or III Clinical Trials in Pediatric Cancer
  • PL05 Phase I, II, or III Clinical Trials in the Elderly
  • PL06 Phase I, II, or III Clinical Trials in Minorities and Medically Underserved Populations

Top of page